Abstract
Insulin glulisine in the management of diabetes Satoru Yamada1,21Diabetes Center, Kitasato Institute Hospital, Tokyo, Japan; 2Department of Internal Medicine, Keio University School of Medicine, Tokyo, JapanAbstract: Insulin glulisine is appealing in principle, but the advantages of this drug over the other rapid-acting insulin analogs are still relatively unknown. The frequency of hypoglycemia, convenience in the timing of administration, and improvements in terms of HbA1c seem similar among the rapid-acting insulin analogs, including insulin glulisine. Only properly randomized long-term clinical studies with insulin glulisine will reveal the true value of this novel insulin analog.Keywords: insulin analog, rapid-acting insulin, trometamol, polysorbate 20
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
